Effect of Host Factors on Hepatitis C Treatment by Sofosbuvir Drug

Abstract

HCV infection is a major public health burden in Egypt, where it bears the highest prevalence rate in the world. A revolution in HCV infection treatment was achieved in the last years marked by the introduction of the direct antiviral agents (DAAs). Optimal therapy for patients with HCV genotype 4 infections is changing rapidly; the standard of care for a long time has been a combination of pegylated-interferon-alpha (PEG-IFN-α) and ribavirin (RBV), with modest response rates and considerable adverse events.